CINCINNATI, Dec. 9 Kendle (Nasdaq: KNDL) aleading, global full-service clinical research organization, today announcedPresident Simon Higginbotham will participate in the annual Raymond JamesBoston Fall Investors Conference. The conference will be held at The StateRoom, 60 State Street, 33rd floor, in Boston on Dec. 11, 2008. Kendle'spresentation is scheduled from 2:30 to 3:15 p.m. Eastern Standard Time.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )
Presentations will not be webcast at the conference. However, slides fromKendle's presentation will be available by 11 a.m. Eastern Standard Time onDec. 11 at http://www.kendle.com under the Investor Events and Presentationssection.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinicalresearch organization providing the full range of early- to late-stageclinical development services for the world's biopharmaceutical industry. Ourfocus is on innovative solutions that reduce cycle times for our customers andaccelerate the delivery of life-enhancing drugs to market for the benefit ofpatients worldwide. As one of the fastest-growing global providers of PhaseI-IV services, we offer experience spanning 90 countries, along withindustry-leading patient access and retention capabilities and broadtherapeutic expertise, to meet our customers' clinical development challenges.
Kendle was recognized by FORTUNE magazine as one of the 100fastest-growing companies in the United States for 2008. The company also hasbeen recognized as "Top CRO to Work With" in the CenterWatch 2007 survey ofU.S. investigative sites and "Best CRO" for 2007 and 2006 by leading globalpharmaceutical publication Scrip World Pharmaceutical News.
Additional information and investor kits are available upon request fromKendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from theCompany's Web site at http://www.kendle.com .
SOURCE Kendle International Inc.